image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Alliance Pharma

July 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 36p
Alliance Pharma, which is building by acquisition a portfolio of generic drugs, has just announced it has bought the worldwide rights to Syntometrine from Novartis for US$11.5m. Syntometrine,  an obstetric drug used in the final stages of labour, has been selling in several countries including Australia, South Africa, Malaysia and New Zealand and in the year to March 2013 total sales were US$3.2m with gross margin generated of US$2.8m. Alliance expects to have annual distribution and operating costs of £0.5m associated with these territories. Earlier at its AGM Alliance noted that trading in the first four months of 2013 has been 6% ahead of last year with Hydromol (dermatology) sales going particularly well.Originall ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Alliance Pharma - Acquires new products (September 2012)
Alliance Pharma (June 2012)
Alliance Pharma (November 2011)
Alliance Pharma - Cambridge Labs nehind its growth (June 2011)
Alliance Pharma (October 2010)
Alliance Pharma (August 2010)
Alliance Pharma - Trading ahead of expectations (July 2010)
Alliance Pharma - Gain reaches 75% in five months (May 2010)
Alliance Pharma - Substantial eps enhancing acquisition (March 2010)
Alliance Pharma - Beats expectations again (February 2010)
Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X